Page 130 - Read Online

Silva Rd, Myers A, Vrieze FW, Singleton A, Hardy J. The tau H2 Rozenberg R, Samii A, Samaddar T, Schulte C, Sharma M,
haplotype is almost exclusively Caucasian in origin. Neurosci Lett Singleton A, Spitz M, Tan EK, Tayebi N, Toda T, Troiano AR, Tsuji S,
2004;369:183‑5. Wittstock M, Wolfsberg TG, Wu YR, Zabetian CP, Zhao Y, Ziegler SG.
71. Skipper L, Wilkes K, Toft M, Baker M, Lincoln S, Hulihan M, Multicenter analysis of glucocerebrosidase mutations in Parkinson’s
Ross OA, Hutton M, Aasly J, Farrer M. Linkage disequilibrium and disease. N Engl J Med 2009;361:1651‑61.
association of MAPT H1 in Parkinson disease. Am J Hum Genet 87. DePaolo J, Goker‑Alpan O, Samaddar T, Lopez G, Sidransky E.
2004;75:669‑77. The association between mutations in the lysosomal protein
72. Fidani L, Kalinderi K, Bostantjopoulou S, Clarimon J, Goulas A, glucocerebrosidase and parkinsonism. Mov Disord 2009 15;24:1571‑8.
Katsarou Z, Hardy J, Kotsis A. Association of the Tau haplotype 88. Goker‑Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M,
with Parkinson’s disease in the Greek population. Mov Disord Sidransky E. The spectrum of parkinsonian manifestations associated
2006;21:1036‑9. with glucocerebrosidase mutations. Arch Neurol 2008;65:1353‑7.
73. Refenes N, Bolbrinker J, Tagaris G, Orlacchio A, Drakoulis N, 89. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y,
Kreutz R. Role of the H1 haplotype of microtubule‑associated protein Minoshima S, Yokochi M, Mizuno Y, Shimizu N. Mutations in the
tau (MAPT) gene in Greek patients with Parkinson’s disease. BMC parkin gene cause autosomal recessive juvenile parkinsonism.
Neurol 2009;9:26. Nature 1998;392:605‑8.
74. Fung HC, Xiromerisiou G, Gibbs JR, Wu YR, Eerola J, Gourbali V, 90. Dekker MC, Bonifati V, van Duijn CM. Parkinson’s disease: piecing
Hellström O, Chen CM, Duckworth J, Papadimitriou A, Tienari PJ, together a genetic jigsaw. Brain 2003;126:1722‑33.
Hadjigeorgiou GM, Hardy J, Singleton AB. Association of tau 91. Periquet M, Latouche M, Lohmann E, Rawal N, De Michele G,
haplotype‑tagging polymorphisms with Parkinson’s disease in Ricard S, Teive H, Fraix V, Vidailhet M, Nicholl D, Barone P,
diverse ethnic Parkinson’s disease cohorts. Neurodegener Dis Wood NW, Raskin S, Deleuze JF, Agid Y, Dürr A, Brice A; French
2006;3:327‑33. Parkinson’s Disease Genetics Study Group; European Consortium
75. Beutler E. Gaucher disease: new molecular approaches to diagnosis on Genetic Susceptibility in Parkinson’s Disease. Parkin mutations
and treatment. Science 1992;256:794‑9. are frequent in patients with isolated early‑onset parkinsonism. Brain
76. Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: 2003;126:1271‑8.
mutation and polymorphism spectrum in the glucocerebrosidase 92. Hedrich K, Eskelson C, Wilmot B, Marder K, Harris J, Garrels J,
gene (GBA). Hum Mutat 2008;29:567‑83. Meija‑Santana H, Vieregge P, Jacobs H, Bressman SB, Lang AE,
77. Tayebi N, Walker J, Stubblefield B, Orvisky E, LaMarca ME, Wong K, Kann M, Abbruzzese G, Martinelli P, Schwinger E, Ozelius LJ,
Rosenbaum H, Schiffmann R, Bembi B, Sidransky E. Gaucher Pramstaller PP, Klein C, Kramer P. Distribution, type, and origin
disease with parkinsonian manifestations: does glucocerebrosidase of Parkin mutations: review and case studies. Mov Disord
deficiency contribute to a vulnerability to parkinsonism? Mol Genet 2004;19:1146‑57.
Metab 2003;79:104‑9. 93. Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C,
78. Lwin A, Orvisky E, Goker‑Alpan O, LaMarca ME, Sidransky E. Shults C, Marder K, Conneally PM, Nichols WC; Parkinson Study
Glucocerebrosidase mutations in subjects with parkinsonism. Mol Group. Heterozygosity for a mutation in the parkin gene leads to
Genet Metab 2004;81:70‑3. later onset Parkinson disease. Neurology 2003;60:796‑801.
79. Aharon‑Peretz J, Badarny S, Rosenbaum H, Gershoni‑Baruch R. 94. Sun M, Latourelle JC, Wooten GF, Lew MF, Klein C, Shill HA,
Mutations in the glucocerebrosidase gene and Parkinson disease: Golbe LI, Mark MH, Racette BA, Perlmutter JS, Parsian A,
phenotype‑genotype correlation. Neurology 2005;65:1460‑1. Guttman M, Nicholson G, Xu G, Wilk JB, Saint‑Hilaire MH,
80. Gan‑Or Z, Giladi N, Rozovski U, Shifrin C, Rosner S, Gurevich T, DeStefano AL, Prakash R, Williamson S, Suchowersky O, Labelle N,
Bar‑Shira A, Orr‑Urtreger A. Genotype‑phenotype correlations Growdon JH, Singer C, Watts RL, Goldwurm S, Pezzoli G, Baker KB,
between GBA mutations and Parkinson disease risk and onset. Pramstaller PP, Burn DJ, Chinnery PF, Sherman S, Vieregge P,
Neurology 2008;70:2277‑83. Litvan I, Gillis T, MacDonald ME, Myers RH, Gusella JF. Influence of
81. Kalinderi K, Bostantjopoulou S, Paisan‑Ruiz C, Katsarou Z, heterozygosity for parkin mutation on onset age in familial Parkinson
Hardy J, Fidani L. Complete screening for glucocerebrosidase disease: the GenePD study. Arch Neurol 2006;63:826‑32.
mutations in Parkinson disease patients from Greece. Neurosci Lett 95. Kay DM, Moran D, Moses L, Poorkaj P, Zabetian CP, Nutt J,
2009;452:87‑9. Factor SA, Yu CE, Montimurro JS, Keefe RG, Schellenberg GD,
82. Neumann J, Bras J, Deas E, O’Sullivan SS, Parkkinen L, Payami H. Heterozygous parkin point mutations are as common
Lachmann RH, Li A, Holton J, Guerreiro R, Paudel R, Segarane B, in control subjects as in Parkinson’s patients. Ann Neurol
Singleton A, Lees A, Hardy J, Houlden H, Revesz T, Wood NW. 2007;61:47‑54.
Glucocerebrosidase mutations in clinical and pathologically proven 96. Chien HF, Rohé CF, Costa MD, Breedveld GJ, Oostra BA,
Parkinson’s disease. Brain 2009;132:1783‑94. Barbosa ER, Bonifati V. Early‑onset Parkinson’s disease caused by a
83. Spitz M, Rozenberg R, Pereira Lda V, Reis Barbosa E. Association novel parkin mutation in a genetic isolate from north‑eastern Brazil.
between Parkinson’s disease and glucocerebrosidase mutations in Neurogenetics 2006;7:13‑9.
Brazil. Parkinsonism Relat Disord 2008;14:58‑62. 97. Periquet M, Lücking C, Vaughan J, Bonifati V, Dürr A, De Michele G,
84. Wan L, Hsu CM, Tsai CH, Lee CC, Hwu WL, Tsai FJ. Mutation Horstink M, Farrer M, Illarioshkin SN, Pollak P, Borg M,
analysis of Gaucher disease patients in Taiwan: high prevalence Brefel‑Courbon C, Denefle P, Meco G, Gasser T, Breteler MM,
of the RecNciI and L444P mutations. Blood Cells Mol Dis Wood N, Agid Y, Brice A; French Parkinson’s Disease Genetics
2006;36:422‑5. Study Group. The European Consortium on Genetic Susceptibility
85. Tayebi N, Stubblefield BK, Park JK, Orvisky E, Walker JM, in Parkinson’s Disease. Origin of the mutations in the parkin gene
LaMarca ME, Sidransky E. Reciprocal and nonreciprocal in Europe: exon rearrangements are independent recurrent events,
recombination at the glucocerebrosidase gene region: implications for whereas point mutations may result from founder effects. Am J Hum
complexity in Gaucher disease. Am J Hum Genet 2003;72:519‑34. Genet 2001;68:617‑26.
86. Sidransky E, Nalls MA, Aasly JO, Aharon‑Peretz J, Annesi G, 98. Hedrich K, Kann M, Lanthaler AJ, Dalski A, Eskelson C, Landt O,
Barbosa ER, Bar‑Shira A, Berg D, Bras J, Brice A, Chen CM, Schwinger E, Vieregge P, Lang AE, Breakefield XO, Ozelius LJ,
Clark LN, Condroyer C, De Marco EV, Dürr A, Eblan MJ, Fahn S, Pramstaller PP, Klein C. The importance of gene dosage studies:
Farrer MJ, Fung HC, Gan‑Or Z, Gasser T, Gershoni‑Baruch R, mutational analysis of the parkin gene in early‑onset parkinsonism.
Giladi N, Griffith A, Gurevich T, Januario C, Kropp P, Lang AE, Hum Mol Genet 2001;10:1649‑56.
Lee‑Chen GJ, Lesage S, Marder K, Mata IF, Mirelman A, Mitsui J, 99. Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A,
Mizuta I, Nicoletti G, Oliveira C, Ottman R, Orr‑Urtreger A, Pfeiffer RF, Marder KS, Foroud T, Nichols WC; Parkinson Study
Pereira LV, Quattrone A, Rogaeva E, Rolfs A, Rosenbaum H, Group‑PROGENI Investigators. Parkin dosage mutations have

124 Neuroimmunol Neuroinflammation | Volume 1 | Issue 3 | December 2014